Bayer Reports Results of Aliqopa (copanlisib) + Rituximab in P-III CHRONOS-3 Study for Relapsed Indolent Non-Hodgkin’s Lymphoma
Bayer Reports Results of Eliapixant (BAY1817080) in P-IIb Study for the Treatment of Refractory Chronic Cough
Shots:
- The P-III CHRONOS-3 study involves assessing Aliqopa (IV) + rituximab vs PBO + rituximab in 458 patients with relapsed iNHL in extending PFS who have received at least one or more lines of prior rituximab-containing treatment
- Results: @median follow-up of 19.2mos., mPFS (21.5 vs 13.8 mos.), ORR (80.8% vs 47.7%), CR (33.9% and 14.6%), no new safety signals were identified, overall improvement in the prognosis of iNHL patients
- Aliqopa is a PI3K inhibitor with inhibitory activity against PI3K-α and PI3K-δ isoforms expressed in malignant B cells. The data is presented at AACR 2021 and simultaneously published in The Lancet Oncology
Click here to read full press release/ article | Ref: Businesswire | Image: Business Standard